Exelixis | EXEL - Stock


Exelixis reported $27.4M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
Acadia Pharmaceuticals USD 29.1M 2.97M Sep/2025
Agios Pharmaceuticals USD 32.92M 886K Dec/2025
Akebia Therapeutics USD 18.64M 1.93M Sep/2025
Amgen USD 6.22B 121M Dec/2025
AstraZeneca USD 6.59B 126M Sep/2025
Bayer EUR 12.33B 221M Sep/2025
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Bristol-Myers Squibb USD 2.76B 21M Sep/2025
Cytokinetics USD 0 0 Dec/2023
Eisai JPY 236.46B 9.14B Sep/2025
Eli Lilly USD 13.74B 1.56B Dec/2025
Esperion Therapeutics USD 108.54M 5.93M Sep/2025
Exelixis USD 27.4M 3.92M Sep/2025
Genmab DKK 13M 1000K Jun/2025
Glaxosmithkline GBP 6.12B 46M Sep/2025
Incyte USD 101.06M 17.61M Dec/2025
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
MacroGenics USD 8.75M 530K Sep/2025
Merck USD 6.44B 157M Sep/2025
Moderna USD 332M 92M Sep/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 69M 300K Dec/2025
Novartis USD 6.42B 114M Sep/2025
Pfizer USD 11.47B 201M Sep/2025
Puma Biotechnology USD 9.48M 885K Sep/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Takeda JPY 1.41T 107.71B Dec/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025